This is comparable to the TTR decrease with patisiran q3w (83–84%) in the APOLLO Phase 3 investigation, where the magnitude of TTR decrease was linked to enhancement in polyneuropathy and a broad spectrum of clinical symptoms. This evidence concerns the gene TTR and polyneuropathy.